0000822370 false 0000822370 2023-10-02 2023-10-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, D.C. 20549






Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): October 2, 2023


Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-35527   87-0419387
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)


21250 Hawthorne Boulevard, Suite 800, Torrance, CA   90503
(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code (310) 214-0065



(Former name or former address, if changed, since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))


Securities registered pursuant to Section 12(b of the Act:


Title of each class   Trading Symbol   Name of each exchange
on which registered


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers 


Appointment of Director


On October 2, 2023, the Board of Directors of Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) appointed George Sekulich to fill a vacancy on the Board of Directors created when Yutaka Niihara, M.D., M.P.H., the former Chairman and Chief Executive Officer, resigned as a director effective September 25, 2023.


Mr. Sekulich, age 58, was recently appointed as Co-President and Chief Commercial Officer of the company and has served as Senior Vice President of Global Commercialization and Chief Information Officer since July 2019.  From September 2014 through July 2019, Mr. Sekulich served as Chief Information Officer of EMI Holdings, Inc. (formerly, Emmaus Life Sciences, Inc.), our wholly owned subsidiary.


There are no family relationships between Mr. Sekulich and any of our other directors, executive officers, or persons nominated or chosen to become a director or executive officer.  Mr. Sekulich is not party to any current or proposed transaction for which disclosure is required under Item 404(a) of Regulation S-K.


Also on October 2, 2023, the Board of Directors appointed Willis Lee, the Co-President and Chief Operating Officer, to serve as Chairman of the Board of Directors.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


Exhibit Number   Description
104   Cover Page Interactive Data File (embedded within the inline XBRL Document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: October 4, 2023 EMMAUS LIFE SCIENCES, INC.
  Name:  Yasushi Nagasaki
  Title: Chief Financial Officer